Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: a randomized placebo-controlled trial

OBJECTIVES: The potential benefit of convalescent plasma (CP) therapy for coronavirus disease 2019 (COVID-19) is highest when administered early after symptom onset. Our objective was to determine the effectiveness of CP therapy in improving the disease course of COVID-19 among high-risk outpatients...

Descripción completa

Detalles Bibliográficos
Autores principales: Gharbharan, Arvind, Jordans, Carlijn, Zwaginga, Lisa, Papageorgiou, Grigorios, van Geloven, Nan, van Wijngaarden, Peter, den Hollander, Jan, Karim, Faiz, van Leeuwen-Segarceanu, Elena, Soetekouw, Robert, Lammers, Jolanda, Postma, Douwe, Kampschreur, Linda, Groeneveld, Geert, Swaneveld, Francis, van der Schoot, C. Ellen, Götz, Hannelore, Haagmans, Bart, Koopmans, Marion, Bogers, Susanne, Geurtsvankessel, Corine, Zwaginga, Jaap Jan, Rokx, Casper, Rijnders, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395229/
https://www.ncbi.nlm.nih.gov/pubmed/36007870
http://dx.doi.org/10.1016/j.cmi.2022.08.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395229/
https://www.ncbi.nlm.nih.gov/pubmed/36007870
http://dx.doi.org/10.1016/j.cmi.2022.08.005

Ejemplares similares